Salah S, Ito K, Kita Y, Kobayashi T, et al. Assessing Response Durability and Survival After Second-Line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk Model. Int J Urol 2025;32:1569-1575.
PMID: 40679106